| Year | Q2 2024 | Q1 2024 |
|---|---|---|
| Total Revenue | 30.77B | 28.93B |
| Cost of Revenue | 16.27B | 15.54B |
| Gross Profit | 14.5B | 13.39B |
| Operating Expenses | 7.05B | 7.65B |
| Research and Development | 0 | 0 |
| Selling, General & Administrative Expenses | 7.05B | 7.65B |
| Selling & Marketing Expenses | 0 | 0 |
| General & Administrative Expenses | 0 | 0 |
| Other Expenses | 0 | 1.01B |
| Operating Income | 7.44B | 5.74B |
| Total Other Income/Expenses Net | 1.05B | 896.9M |
| Income Before Tax | 8.49B | 6.64B |
| Income Tax | 1.9B | 1.25B |
| Net Income | 6.53B | 5.36B |
| Basic EPS | 16.31 | 13.39 |
| EPS Diluted | 16.28 | 13.37 |
| Basic Average Shares | 400.66M | 400.64M |
| Diluted Average Shares | 401.39M | 401.26M |
| EBITDA | 9.62B | 7.82B |
Mankind Pharma Limited
MANKIND.NS
NSE
2350.5INR36.55 (1.58%)
MANKIND.NS Financial Statements
Retained Earning Schedule
| Year |
|---|
| Retained Earnings (Previous Year) |
| Net Income |
| Stock Repurchases |
| Dividend Paid |
| Retained Earnings |
| Other Distributions |
PPE Schedule
| Year |
|---|
| Gross PPE |
| Annual Depreciation |
| Capital Expenditure |
| Net PPE |
Intangible and Goodwill Schedule
| Year |
|---|
| Acquisitions and Adjustments |
| Goodwill (Previous Year) |
| Goodwill |